By Fineline Cube 
Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China’s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS ≥1), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA’s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication approval |
| Product | KEYTRUDA (pembrolizumab) |
| Indication | Perioperative treatment of adult patients with resectable locally advanced HNSCC, PD-L1 positive (CPS ≥1) by validated test |
| Treatment Regimen | Neoadjuvant pembrolizumab monotherapy → adjuvant pembrolizumab + radiotherapy ± cisplatin → pembrolizumab monotherapy continuation |
| Date | 03 Sept 2026 |
| Distinction | First and only PD-1 inhibitor approved for perioperative resectable locally advanced HNSCC |
Drug Profile & Treatment Regimen
- Molecule: pembrolizumab (KEYTRUDA), a PD-1 inhibitor developed by Merck (MSD)
- Biomarker Requirement: Tumors must express PD-L1 with a Combined Positive Score (CPS) ≥1, determined by a validated test
- Approved Perioperative Regimen:
- Neoadjuvant phase: Pembrolizumab monotherapy prior to surgery
- Adjuvant phase: Pembrolizumab in combination with radiotherapy, with or without cisplatin
- Continuation phase: Pembrolizumab monotherapy
- Strategic Significance: The approval moves KEYTRUDA from the recurrent or metastatic HNSCC setting into the resectable locally advanced stage — earlier in the disease course where treatment intent is curative
Clinical & Competitive Positioning
- As the first and currently only PD-1 inhibitor approved for perioperative treatment of resectable locally advanced HNSCC, KEYTRUDA occupies an uncontested category in this indication
- The biomarker-selected, multi-phase regimen establishes a new treatment paradigm for a patient population historically managed with surgery and chemoradiotherapy alone
- The approval further expands KEYTRUDA’s already broad footprint across head and neck cancer indications in China
Market Impact & Outlook
- Curative-intent expansion: Shifting immunotherapy into the resectable setting captures patients earlier, extending treatment duration and deepening KEYTRUDA’s commercial footprint in HNSCC
- First-mover moat: As the only approved PD-1 inhibitor in perioperative HNSCC, KEYTRUDA faces no direct immuno-oncology competition in this indication at launch
- Biomarker-driven adoption: The CPS ≥1 requirement channels testing and diagnosis infrastructure, reinforcing companion diagnostic uptake alongside therapy adoption
- Portfolio momentum: The approval strengthens MSD’s (NYSE: MRK) oncology franchise in China, where perioperative immunotherapy is becoming a central battleground across solid tumor types
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug commercialization, clinical adoption and market potential are forward-looking and subject to risks and uncertainties, including competitive developments, reimbursement outcomes and prescribing patterns. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech